Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2131

1.

Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer.

Sakaguchi K, Ono H, Nakatsukasa K, Ishikawa T, Hasegawa Y, Takahashi M, Niikura N, Koizumi K, Sakurai T, Shigematsu H, Takahashi S, Taira S, Suzuki M, Narui K, Miura D, Yamada K, Yoshimura M, Shioya H, Konishi E, Isao Y, Imai K, Fujikawa K, Taguchi T; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society.

Medicine (Baltimore). 2019 Aug;98(32):e16770. doi: 10.1097/MD.0000000000016770.

2.

Role of testosterone and androgen receptor in periodontal disease progression in female rats.

Steffens JP, Valenga HM, Santana LCL, Albaricci MCDC, Kantarci A, Spolidorio LC.

J Periodontol. 2019 Aug 7. doi: 10.1002/JPER.19-0099. [Epub ahead of print]

PMID:
31389012
3.

Long-Term Survival and Complete Response to Anastrozole in Breast Cancer Patient With Cutaneous Metastases Only.

Sedloev T, Vlahova A, Usheva S, Vasileva-Slaveva M, Spiridonova T, Spirdonov J.

Anticancer Res. 2019 Aug;39(8):4393-4398. doi: 10.21873/anticanres.13609.

PMID:
31366535
4.

PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression.

Kok PS, Beale P, O'Connell RL, Grant P, Bonaventura T, Scurry J, Antill Y, Goh J, Sjoquist K, DeFazio A, Mapagu C, Amant F, Friedlander M; PARAGON Investigators.

J Gynecol Oncol. 2019 Sep;30(5):e86. doi: 10.3802/jgo.2019.30.e86.

5.

Not everything is as it seems: a rare form of metastatic breast cancer.

Rocha M, Azevedo D, Teira A, Barbosa M.

Autops Case Rep. 2019 Jun 11;9(2):e2018085. doi: 10.4322/acr.2018.085. eCollection 2019 Apr-Jun.

7.

Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy.

Glaser RL, York AE.

Int J Pharm Compd. 2019 Jul-Aug;23(4):325-339.

PMID:
31315085
8.

Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer.

Patterson-Lomba O, Dalal AA, Ayyagari R, Liu O, Dervishi E, Platt E, Chandiwana D, O'Shaughnessy JA.

Breast J. 2019 Jul 9. doi: 10.1111/tbj.13345. [Epub ahead of print]

PMID:
31290203
9.

PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.

Tang M, O'Connell RL, Amant F, Beale P, McNally O, Sjoquist KM, Grant P, Davis A, Sykes P, Mileshkin L, Moujaber T, Kennedy CJ, deFazio A, Tan K, Antill Y, Goh J, Bonaventura T, Scurry J, Friedlander M.

Gynecol Oncol. 2019 Jun 18. pii: S0090-8258(19)31322-8. doi: 10.1016/j.ygyno.2019.06.011. [Epub ahead of print]

PMID:
31227223
10.

Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation.

Ward MC, Vicini F, Chadha M, Pierce L, Recht A, Hayman J, Thaker NG, Khan A, Keisch M, Shah C.

Int J Radiat Oncol Biol Phys. 2019 Jun 15. pii: S0360-3016(19)30849-1. doi: 10.1016/j.ijrobp.2019.06.014. [Epub ahead of print]

PMID:
31212043
11.

Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer.

Ingle JN, Kalari KR, Momozawa Y, Kubo M, Furukawa Y, Shepherd LE, Ellis MJ, Goss PE, Barman P, Carlson EE, Sinnwell JP, Tang X, Goetz MP, Chen BE, Cairns J, Weinshilboum RM, Wang L.

Pharmacogenet Genomics. 2019 Jun 17. doi: 10.1097/FPC.0000000000000382. [Epub ahead of print]

PMID:
31211741
12.

Effect of local aromatase inhibition in endometriosis using a new chick embryo chorioallantoic membrane model.

Pluchino N, Poppi G, Yart L, Marci R, Wenger JM, Tille JC, Cohen M.

J Cell Mol Med. 2019 Aug;23(8):5808-5812. doi: 10.1111/jcmm.14372. Epub 2019 Jun 14.

13.
14.

Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.

[No authors listed]

N Engl J Med. 2019 Jun 6;380(23):2282. doi: 10.1056/NEJMx190018. No abstract available.

PMID:
31167077
15.

Temperature/pH-Triggered PNIPAM-Based Smart Nanogel System Loaded With Anastrozole Delivery for Application in Cancer Chemotherapy.

Singh A, Vaishagya K, K Verma R, Shukla R.

AAPS PharmSciTech. 2019 Jun 4;20(5):213. doi: 10.1208/s12249-019-1410-3.

PMID:
31165298
16.

Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.

Ruíz-Borrego M, Guerrero-Zotano A, Bermejo B, Ramos M, Cruz J, Baena-Cañada JM, Cirauqui B, Rodríguez-Lescure Á, Alba E, Martínez-Jáñez N, Muñoz M, Antolín S, Álvarez I, Del Barco S, Sevillano E, Chacón JI, Antón A, Escudero MJ, Ruiz V, Carrasco E, Martín M; GEICAM.

Breast Cancer Res Treat. 2019 Aug;177(1):115-125. doi: 10.1007/s10549-019-05296-8. Epub 2019 May 31.

PMID:
31152327
17.

Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer.

Hannouf MB, Zaric GS, Blanchette P, Brezden-Masley C, Paulden M, McCabe C, Raphael J, Brackstone M.

Pharmacogenomics J. 2019 May 27. doi: 10.1038/s41397-019-0089-x. [Epub ahead of print]

PMID:
31130722
18.

Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903.

Mileshkin L, Edmondson R, O'Connell RL, Sjoquist KM, Andrews J, Jyothirmayi R, Beale P, Bonaventura T, Goh J, Hall M, Clamp A, Green J, Lord R, Amant F, Alexander L, Carty K, Paul J, Scurry J, Millan D, Nottley S, Friedlander M; PARAGON study group.

Gynecol Oncol. 2019 Jul;154(1):29-37. doi: 10.1016/j.ygyno.2019.05.007. Epub 2019 May 23.

PMID:
31130288
19.

Multisystemic Benign Metastasizing Leiomyoma: An Unusual Condition with an Atypical Clinical Presentation.

Matos F, Santiago C, Silva D.

Case Rep Radiol. 2019 Apr 10;2019:7014248. doi: 10.1155/2019/7014248. eCollection 2019.

20.

[The medical aspect of using anabolic androgenic steroids in males attending gyms of Saint-Petersburg].

Lykhonosov MP, Babenko AY.

Probl Endokrinol (Mosk). 2019 May 14;65(1):19-30. doi: 10.14341/probl9832. Russian.

PMID:
31091047

Supplemental Content

Loading ...
Support Center